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Abstract  Complex  regional  pain  syndrome  is a  chronic  and  painful  condition  that affects  the
quality of  life  of  patients.  It  is  usually  triggered  by  a  traumatic  event  of  the  soft  tissues  involv-
ing the  nervous  tissue.  Although  the  factors  that  cause  the  syndrome  are  varied  and  not  well
known, different  etiopathologic  concepts  have  been  proposed  to  explain  the  presence  of  this
syndrome,  such  as  autonomic  dysfunction  and  changes  in  CNS  plasticity,  among  others.  The
patient characteristically  presents  pain,  sensory  abnormalities,  vasomotor  disturbances  in the
skin, edema,  changes  in sweating,  and  motor  alterations.  The  pain  is  associated  with  changes
in the  autonomic  nervous  system  and has  a  distal  predominance.  Since  there  is no definitive
diagnostic test,  diagnosis  is  mainly  based  on  a  complete  medical  history  and  physical  examina-
tion.  Treatment  is multidisciplinary  and  based  on  pain  relief.  Although  in most  cases  evolution  is
favorable,  rapid  diagnosis  and  treatment  are  recommended  to  avoid  dystrophic  stage  as much
as possible.
© 2014  Universidad  Autónoma  de Nuevo  León.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Introduction
The  first  description  of  complex  regional  pain  syndrome
(CRPS)  dates  from  the  seventeenth  century  and was  reported
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by  the French  surgeon  Ambroise  Paré  to  describe  persis-
tent  pain  and  contractures  of  the  arm  suffered  by  King
Charles  IX  after  the  bloodletting  to which  he  was  sub-
jected.  During  the American  Civil  War, Mitchell  described
cases  in which  the  soldiers  suffered  from  burning  pain
secondary  to  gunshot  wounds.  This  was  described  as  causal-
gia.  In  1900  Sudeck  described  traumatic  complications
in  the  extremities  characterized  by  intractable  pain,
edema,  and  limitations  in motor  function.  Lerich in
1916,  suggested  that  causalgia  was  caused  by  exces-
sive  activity  of  the sympathetic  nervous  system.  It  was
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not  until  1946  when  Evans  proposed  reflex  sympathetic
dystrophy.1
In  1979  the  International  Association  for  the Study  of
Pain  (IASP)  defined  causalgia  as  ‘‘a  syndrome  of  sustained,
burning  pain  after  a traumatic  nerve  injury,  combined  with
vasomotor  and sudomotor  and  later  trophic  changes’’  and
reflex  sympathetic  dystrophy  as  ‘‘similar,  but  from  other
causes.’’1
The  term  proposed  by  the IASP  in 1994,  which  differen-
tiates  complex  regional  pain  syndrome  into  type 1  and  2, is
currently  used  with  the dissimilarity  that  type 1  is  caused  by
an  injury  or  trauma  to  tissue  and  in  type 2  there  is  prior  and
obvious  neurological  damage.
Since  the characteristics  of  these two  types  of  disease  are
essentially  the  same  and treatment  is  not  different,  the  rest
of  this  text  will  not  distinguish  between  them with  respect
to  pathophysiology,  diagnosis or  treatment.
Epidemiology
Worldwide,  the incidence  and  prevalence  of CRPS  is
unknown.  Some  studies  have reported  an incidence  rate  that
ranges  from  5.46  to  26.2  per  100,000  persons  year.2,3 In  addi-
tion,  the  prevalence  subsequent  to  trauma  ranges  from  0.03
to  37%,  based  on  retrospective  studies.  In 40%  of cases  it is
associated  with  a  fracture  or  surgery,  with  compression  of
the  median  nerve  being  the  most  common,  although  it can
also  appear  after a  sprain  (10%),  root  lesions  (9%),  lesions
of  the  spinal  cord  (6%), and  spontaneously  (5--10%).  It  was
found  that  it  more  frequently  affects  women  (2--3:1)  with  a
peak  between  50  and 70  years  of  age,  with  a  predominance
in  the  arms.4
It  is  noteworthy  that  the severity  of  the  original  injury  is
not  correlated  with  the  severity  of  the symptoms  of  CRPS,
although  psychological  factors  such as  stress  are risk  factors
that worsen  symptomatology.5
CRPS  is  also  associated  with  other  diseases  and  conditions
such  as  stroke,  mastectomy,  pregnancy,  and  the use  of  drugs
such  as  phenobarbital  and isoniazid.  There  are predisposing
factors  for  the development  of  this  syndrome  in addition  to
trauma  and  diabetes  mellitus.6
The  main  feature  of  the  history  is  a  fracture,  and immo-
bilization  has  been  proposed  as  a  possible  predisposing
factor  for  CRPS.  Immobilization  studies  in  animals  have
found  increased  sensitivity  to  stimuli,  and  changes  at the
spinal  level.  In  humans  it  was  found  that plaster  splint
immobilization  results  in an  increase  in  cerebral  blood
flow  in  areas  related  to  sensory,  motor,  and emotional
processing.7
It  is  believed  that  psychogenic  or  hysterical  factors,
mainly  associated  with  depressive  symptoms,  may  con-
tribute  to  CRPS. Any psychological  factor  can  interact  with
catecholamine  release  and  thus  interfere  with  the patho-
physiological  mechanisms  mentioned;  however  this is  only a
hypothesis.8 The  success  of  psychotherapy  and occupational
and  cognitive  therapy  in CRPS  patients  shows  that  the symp-
toms  of  dystonia  and  myoclonus  are of  a  psychogenic  origin
in  some  patients.  It  is  not  always  easy  to  distinguish  these
symptoms  from  simulation.9
CRPS  often  occurs  in several  family members  and at
younger  ages,  which  may  indicate  a genetic  predisposition.
Accordingly,  HLA has  been  proposed  to have  a role  in CRPS.
Genetic  studies  have also  identified  polymorphisms  in the
TNF- gene  and  the  angiotensin  converting  enzyme  gene,
but  no contrasting  results  have  been  found  with  the latter.10
Studies  have  shown  that  the use  of  ACE  inhibitors  at
the  time  when  the  causal  trauma  is  suffered,  as  well  as
a  medical  history  of  asthma  or  migraines,  is  associated
with  an increased  risk  of  developing  CRPS.  It is  notewor-
thy  that  these  factors  imply  underlying  inflammation,  since
ACE  inhibitors  increase  the availability  of  substance  P,  and
both  migraines  and  asthma  share  neurogenic  inflammation
mechanisms.10
Pathophysiology
CRPS  is  a  chronic  pain  condition  that  usually  arises  after
a  traumatic  event  of  the  soft  tissues.  The  ‘‘definitive’’
cause  still  remains  unknown,  although  different  patho-
genetic  concepts  have been  proposed;  three  of  the most
studied  are:  autonomic  dysfunction,  neurogenic  inflamma-
tion,  and  changes  in CNS  neuroplasticity,  all  of which  are
still  in dispute.  However,  current  evidence  shows  that this
problem  could  have  a  multifactorial  origin.
Autonomic  dysfunction
Refers  to an alteration  of  the  sympathetic  nervous  system.
It  has been  suggested  that  its  degree  depends  on  the  stage
in  which  the syndrome  is  found.  This  suggests  the  exist-
ence  of inhibition  of  sympathetic  vasoconstrictor  neurons,
expressing  lower  levels  of  norepinephrine  in  the  affected
limb  compared  to  its counterpart.  This  triggers  vasodilation,
and  chronicity  of  this condition  allows  vasoconstriction.
This  chronicity  contributes  to  a redistribution  of  blood  flow
through  arterioles,  causing  inadequate  capillary  nutrition,
which  results  in  hypoxemia  and  acidosis.  These  alterations
can  produce  free  radicals,  which  cause  histopathological
changes  by oxidative  stress.
There  is  evidence  of  an increase  in the number  of  -
adrenergic  receptors  in the skin  of  patients  with  CRPS.
Their  activation  would  trigger  an increase  in noradrenaline
release,  which  in turn  produces  hyperstimulation  of  noci-
ceptive  fibers  causing pain  and hyperalgesia,  even  in
sympathectomized  patients.
Cutaneous  injection  of  norepinephrine  induces  pain  via
these adrenoreceptors  in  patients  who  respond  to  sympa-
thetic  blockade,  whereas  there  is  no  reaction  in patients
who  showed  no  response  to  the  blockade.  These  data  imply
that  CRPS  may  involve  abnormal  adrenoreceptors  expressed
in  nociceptors  which,  when  stimulated  by circulating  cat-
echolamines,  are activated  and  cause  hyperalgesia  and
possibly  alodinia.11
Another  group  of researchers  found  that  in CRPS II, nerve
damage  causes  an upward  regulation  of catecholamine
receptors  (Fig.  1).
Catecholamine  levels
Plasma  norepinephrine  levels  were lower  in the affected
limb  compared  to  its  healthy  counterpart.  However
adrenaline  levels  were  similar  in  both  extremities.6
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Figure  1  Clinical  manifestations  of  CRPS  and  pathophysiolo-
gical  mechanisms  proposed  to  each.
Inflammation
Recent  studies  suggest  the existence  of  two  different
sources  of  inflammation:  Acute,  tissue  damage  mediated
by  classical  inflammation  mechanisms  (IL-1,  IL-6,  TNF-
alpha,  CD4,  macrophages,  neutrophils)  and  neurogenic,
mediated  by  proinflammatory  cytokines  and  neuropeptides
released  directly  by  nociceptors  in response  to  various
causal  factors.8
The  following  are related  substances:
Not  sympathetic  neurotransmitters
Substance  P,  one  of  the  principal  pain  mediators  and a
vasodilator,  triggers  mast  cell  degranulation  and  activates
osteoblasts.
The  calcitonin  gene-related  peptide  (CGRP)  is a  vasodila-
tor  that  plays  a  role  in  glandular  secretion,  is  involved
in  sensory  transmission,  and  stimulates  endothelial  cell
growth.  Bradykinin  has  also  been  associated.
Sympathetic  neurotransmitters
Vasoactive  intestinal  peptide  is  located  in  the bones and
promotes  bone  resorption,  in addition  to  being a vasodila-
tor  and  stimulating  sweat  gland  secretion.  Neuropeptide
Y  is  a  potent  vasoconstrictor  that enhances  the effects  of
adrenaline.  It  is the  most abundant  peptide  in the  CNS  and
its  periphery.6,8
The  nociceptive  stimulus  not  only  causes  an inflam-
matory  response,  but  also  a low  pain  threshold.  Recent
research  has  shown  that  some  patients  respond  to
treatment  with  immunoglobulins,  and  of  those,  most
carry  serum  IgG autoantibodies  directed  against  autonomic
receptors.12
Sensitization
Peripheral: After tissue  injury,  local  primary  afferent  fibers
release  various  substances,  which  sensitize  nociceptive
nerve  endings  to  other  substances  such  as  histamine  and
bradykinin,  contributing  to  the  development  of  hyperalgesia
and  allodynia.8 Sympathetic  denervation  causes  an  increase
in  the sensitivity  of  blood  vessels  to  catecholamines,  pro-
duced  by  an  increase  in the  number  or  sensitivity  of
adrenoceptors.  This  increase  may  be responsible  for  the
decrease  in  blood  flow  to  the skin  in chronic  conditions.  It
is  hypothesized  that  sympathectomy  causes  sensitization  in
the  long-term,  which  could  explain  why  some patients  have
transient  benefits.
Central:  It has been  found  that  N-methyl  d-aspartate
(NMDA)  receptors  play  an  important  role in central  sensitiza-
tion;  two  controlled  clinical  trials  showed  that  low  doses  of
ketamine  (an  NMDA  antagonist)  dramatically  reduce  pain  in
patients  with  CRPS.13
Moreover,  electrical  stimulation  of nociceptive
mechanical-insensitive  fibers  (CMiHI), characterized  by
a  large electrical  excitation  threshold  and  innervation  of
wide  areas,  can  be the  cause of  secondary  hyperalgesia.
In  studies,  low-frequency  stimulation  caused  mechanical
hyperalgesia  and hypoesthesia,  whereas  high  frequency
stimulation  generated  hypoalgesia  and  hypoesthesia.  It  was
also  found  that  pain  itself  can  trigger  inhibitory  mechanisms
which  develop  hypoalgesia;  this  type  of  pain  relief  is  known
as  ‘‘counter  irritation’’.14
Microvascular  pathology  of  soft tissues
This  hypothesis  suggests  an  underlying  cause  in muscle,
bone  and  perineural  microvasculature  that  cuases  ischemia
and  subsequent  inflammation  originating  persistent  abnor-
mal  pain,  creating  central  sensitization.  Coderre  et  al.,
in  2004,  developed  a mouse  model  that they  called  CPIP
(chronic  post-ischemia  pain), which  involved  a period  of
ischemia-reperfusion  produced  by  placing  a  tourniquet  on
the  hind leg  of  a rat,  then  withdrawing  it  and  recording
their  findings.  They observed  a  reduction  in  the  density
of  sensory  fibers  and capillaries,  spontaneous  afferent  dis-
charge,  decreased  blood  flow,  elevated  malondialdehyde
(free  radical  product  of  lipid peroxidation)  then,  when
attenuated  by  antioxidants,  there  was  a  dose-dependent
improvement  in  allodynia  in the animal.  They  also  observed
an  increase  in the  production  of proinflammatory  cytokines,
an increase  in lactate  levels  in the limb  subjected
to  ischemia-reperfusion  and  hypersensitivity  to  norepi-
nephrine;  symptoms  similar  to  some  patients  with  CRPS
type  I.15
This  steady  state  of  inflammation  due  to  partial  or  inter-
mittent  ischemia  ended  up  causing endothelial  dysfunction,
which  could  explain  the increase  in constriction,  tissue
hypoxia,  metabolic  acidosis,  and increased  permeability  to
macromolecules.  Chronic  ischemia  can also  lead  to  a state  of
capillary  ‘‘no-reflow’’  where  the  decrease  in  vessel  lumen is
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not  only  functional,  but  also  physical;  this  could  also  explain
why  some  patients,  after  undergoing  sympathetic  blockade,
do  not  improve.7
Central  changes
Neuroplasticity:  Janin  and  Baron  were  the  first  to  suggest  a
central  origin  in  the  pathophysiology  of  CRPS.  It  is  currently
known  that  chronic  pain  can  create  a change  in the  cortical
representation  of  the affected  area, in particular,  the repre-
sentation  of  the  affected  area  or  limb  in  the somatosensory
cortex  (S1)  which  is  relatively  small  compared  to  the healthy
limb.8
Spinal  neurons  may  increase  their  sensitivity  in response
to  nociceptive  bombardment  caused  by  autonomic  changes.
A  reorganization  of the primary  somatosensory  area  can
be  generated  in the  supraspinal  space,  as  in  amputee
patients,  demonstrated  by  MRI;  due  to  this,  it is  said
that  peripheral,  spinal,  and supraspinal  nociceptive  cor-
tical  processing  scales  are  involved  in the genesis  of
CRPS.5
It  is  recognized  that  this neuronal  plasticity,  induced
by  pain,  causes  hyperalgesia  but  it  can  also  cause
hypoalgesia  and  hypoesthesia.  Several  studies  show that
neuronal  plasticity  may  be  a decline  effect  in response  to
pain.14
Altered  functional  connectivity  in the  resting  state
In  recent  years,  there  have been  several  studies  regarding  an
alteration  in  the interconnections  of  different  brain  regions
in  patients  with  CRPS.  This  is  based  on  previous  research
of  chronic  pain  that has  demonstrated  a  spatiotemporal  dis-
ruption  in  functional  connectivity  at  rest,  also  known  as  DMN
(default  mode  network),  which  shows  an increase  in diffuse
interconnections,  unlike  control  groups.  These  areas  show a
proportional  correlation  to  the intensity  of pain  experienced
by  patients.16
Dysfunction  in the  motor  cortex
Because  pain  can  interfere  with  the  processing  of  afferent
signals  that  contribute  to  the sense  of positioning,  and the
mental  image  of  the  affected  limb  is  distorted  in patients
with  CRPS,  proprioception  could  be  significantly  affected.
There  are  observations  that  these  patients  need to  carefully
look  at  their  affected  limb  to  control  movements,  making
it  possible  for  them  to  compensate.17 However,  more  and
better  studies  are required  to  have  consistent  evidence,
since  the  only  significant  fact that  has  been  found  is  an
area  of  spatial  representation  of  S1  lower  on  the side  of the
affected  limb,  unlike  its  healthy  counterpart  or  in  control
groups.18
Clinical manifestations
The  onset  of clinical  manifestations  may  be  hours  or  even
months  after  the  noxious  event,  characteristically  they
includes  a  triad  of  autonomic,  sensory  and motor  abnormal-
ities.
Autonomic  alterations
Among  these  alteration  we  can find  early  onset  distal
edema  (in  its  soft and  congestive  form)  in up to  80%  of
cases,  as  well  as  changes  in skin color  and  temperature,
which is  reddish  and  hyperemic  (≥1 ◦C in comparison  to
the  other  limb),  usually  in  the early  stages;  however,  in
40%  of  cases  it can  progress  with  decreased  skin  tempera-
ture and pallor.  Sudomotor  phenomena,  such as  hypohidrosis
or  hyperhidrosis  (the  latter  being  the most  common)  are
also  seen;  trophic  changes,  which  can present  as  excessive
hair  growth,  thin  nails,  and  skin  atrophy,  evidenced  by  the
appearance  of  ‘‘glowing’’  skin,  thinning  of  the epidermis
and  muscle atrophy,  as  well  as  contractures,  are also  found.
Finally,  another  alteration  that  is  present  in  some cases  is
bone  atrophy,  which  can  be associated  with  osteoporosis
(Figs.  2 and  3).
The  main  and  most  common  symptom (90%) is  pain,
which  is  described  as  burning  or  stinging.  It is  usually  felt
as  deep  (68%)  rather  than  superficial  (32%)  pain.  It  can
be  exacerbated  after temperature  changes,  exercise  or
episodes  of  stress  and/or  anxiety,  and there  have  been
cases  where  it increases  at night.  Pain  is  often  accom-
panied  by  other  phenomena  such  as  hyperalgesia  and
allodynia.  Of  these  the  most  important  is  muscle  weak-
ness;  other  manifestations  in  this  category  are essential
tremors  in the  affected  limb,  myoclonus  and  dystonia,
which  is  most frequently  observed  in  patients  with  type  II
CRPS.
It  is  important  to  remember  that the  manifestations  may
change  depending  on  the  location  of  the condition.  Prox-
imal  and deep  joints  undergo  a  reduction  in  function.19
This  differs  from  other  neuropathic  syndromes  due  to  the
presence  of edema,  vasomotor  and  sudomotor  changes,  in
addition  to  an orthostatic  component  which  is  reduced  in
intensity  when the  limb  is  raised,  and increased  when  it is
held  down.5 It  was  thought  that  CRPS  could  have  a temporal
progression  of  symptoms;  however,  this idea  was  rejected
by  the International  Association  for  the Study  of  Pain
(IASP).1
Diagnosis
There  are no pathognomonic  signs  or  symptoms  and  there
is  no definitive  diagnostic  test.  Diagnosis  is  based on  a
complete  medical  history  that  includes  the severity  and
duration  of symptoms  and  signs,  fracture  type  and sever-
ity  of  the  injury  and  physical  examination  of  the affected
limb.20
The  IASP  published  a review  of the clinical  diagnostic
criteria  in 2007  called  the  ‘‘Budapest  Criteria’’,  which  has
a sensitivity  of  85%  and  a specificity  of  69%  (Table  1).  There
must  be regional  pain  that  exceeds  a dermatome  or  a single
nerve  territory,  continuous  or  evoked  pain  of  an intensity
and/or  duration  disproportionate  to  the trauma  or  injury
that  may  have caused  it, and  which  is  associated  with  a
range  of symptoms  and signs  of  sensory,  motor,  vasomotor,
sudomotor  and trophic  disturbances.  Symptoms  and  signs
can  be  variable  depending  on  the time  of  evolution  of  the
syndrome.4 There  are other  approaches  to  the  diagnosis,
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Table  1  IASP  Diagnostic  criteria  for  complex  regional  pain  Syndrome  (2007  Budapest  criteria).
1.  Continuous  pain  disproportionate  to  the  event  that  caused  it
2. Symptoms  (must  meet  at least  one  symptom  in three  of  the  four  categories)
Sensory:  hyperesthesia  and/or  allodynia
Vasomotor:  asymmetry  in  skin  temperature  and/or  asymmetry  of  skin  color  and/or  changes  in skin  color
Sudomotor:  edema  and/or  sweating  changes  and/or  asymmetric  sweating
Motor: decreased  range  of  motion  and/or  motor  dysfunction  (tremor,  dystonia,  weakness)  and/or  trophic  changes  (skin,
hair, nails)
3.  Signs  (must  meet  at  least  one  sign  in  two or  more  of  the four  categories)
Sensory:  evidence  of  hyperalgesia  (to  puncture)  and/or  allodynia  (touch/temperature/deep  pressure/joint  movement)
Vasomotor: asymmetry  in  skin  temperature  >1 ◦C and/or  asymmetry  of  skin  color  and/or  changes  in  skin  color
Sudomotor:  evidence  of  edema  and/or  sweating  changes  and/or  asymmetric  sweating
Motor: evidence  of  decreased  range  of  motion  and/or  motor  dysfunction  (tremor,  dystonia,  weakness)  and/or  trophic
changes (skin,  hair,  nails)
4.  Rule  out  other  conditions  that  may  explain  the  previous  symptoms  and signs.
Figure  2  (a)  Female  patient  with  right  upper  limb  CRPS  affected  before  treatment.  (b)  Same  patient  with  hyperemic,  shiny  bow
and decreased  range  of  motion  secondary  to  the  presence  of  edema,  during  initiation  of  treatment  with  infusion  pump  (Ropivacaine
2%/20 days22).
such  as  the  diagnostic  criteria  of  Kozin  (Table 2)  and  Veldman
(Table  3).
Complementary  tests
Radiography
An  ill-defined  subchondral  heterogeneous  ‘‘mottled’’  dem-
ineralization  of  varying  intensity  is observed  with  a
sensitivity  of  73%  and  a  specificity  of 57%, maintaining  a
regional  character  in later  stages  of  the  disease.20
Gammagraphy
This  study  is  recommended  in stages  I  and II  with  a sensitivity
of  97%  and a  specificity  of  86%.  Its  main  use  is for  the  early
diagnosis  of  CRPS.  In the  initial  stages,  intense  and early
bone  hyper-uptake  that  exceeds  the limits  of  the affected
joint  is  seen.20
Figure  3  Female  with  upper  member  CRPS  affected,  poste-
rior entitled  to  20  days of  completing  treatment  with  infusion
pump  to  the infraclavicular  brachial  plexus  (Ropivacaine  2%22).
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Table  2  Kozin  diagnostic  criteria.
1.  Pain  and  tenderness  of a  limb
2. Symptoms  or  signs  of unsteadiness
Raynaud’s  Phenomenon
Cold,  pale  skin
Hot  or  erythematous  skin
Hyperhidrosis
3.  Swelling  of  limb
Edema  with  or  without  fovea
4. Trophic  skin  changes
Atrophy
Desquamation
Hypertrichosis
Hair  loss
Nail  changes
Thickening  of  the  palmar  aponeurosis
Defined: meets 4  criteria; probable: meets criteria 1, 2, and 3;
possible: meets criteria 1 and 2.
Magnetic  resonance  imaging
This  method  provides  a differential  diagnosis  with
osteonecrosis,  especially  of  the hip. It also  provides
information  about  bone  marrow  edema,  alteration  of soft
tissue,  and  the presence  of joint  effusion.6
Skin  fluximetry  by  the  laser  doppler  technique
This  is  one  of the  most  precise  techniques  that  are  currently
available  for  the  early  diagnosis  of  CRPS  I.  It provides  infor-
mation  of  changes  in  flow,  volume  and  velocity  of cutaneous
microvascularity  in  CRPS  I  in stages  I  and  II.
Thermography
An  increase  in  local  temperature,  especially  in  the  first
weeks  of  development,  is  found,  although  this is  not a con-
sistent  finding  (sensitivity  45%).21
Differential  diagnosis
The  differential  diagnosis  will  depend  on the  stage  of  evo-
lution.  In the  initial phase, infectious  arthritis,  rheumatic
arthritis,  inflammatory  joint  disease,  peripheral  arterial
disease  and  deep  vein thrombosis  should be  considered.
In  the  chronic  phase,  Dupuytren’s  disease,  scleroderma,
Table  3  Veldman  diagnostic  criteria.
1  The  presence  of 4--5  of the  following:
Unexplained  diffuse  pain
A  difference  in  skin  color  in  relation  to  another  extremity.
Diffuse  edema
A difference  in  skin  temperature  relative  to  another
extremity.
Limited  range  of  active  motion.
2.  Occurrence  or  increase  in  the  above  signs  and  symptoms
after use.
3.  The  above  signs  and  symptoms  are  present  in  a  larger
area than  the  primary  area  of  injury  or  operation  and
includes  the  area  distal  to the  primary  lesion.
Table  4  Differential  diagnosis  of  CRPS.
• Deep  vein  thrombosis
• Thrombophlebitis
• Cellulite
• Lymphedema
• Vascular  insufficiency
• Infectious  arthritis
• Rheumatoid  arthritis
• Inflammatory  arthropathy
• Dupuytren’s  disease
and  plantar  fasciitis  should  be taken  into  account.  In hip
conditions,  osteonecrosis  and coxitis  should  be ruled  out.  If
there  is  bone  demineralization,  it would  be  recommended
to  rule  out  osteoporosis  and  bone  tumors  (Table  4).20
Treatment
Early  treatment  is  necessary  to  achieve  complete  recovery
and  prevent  damage.  Treatment  of  CRPS  requires  a  multidis-
ciplinary  approach  to pain  management  which  is  also  aimed
at  functional  recovery  of the  affected  limb.
Pharmacotherapy
Nonsteroidal  antiinflammatory  drugs (NSAIDs),  corticoste-
roids,  cyclooxygenase  (COX)  2  inhibitors  and  free  radical
scavengers  are used with  the  intention  of  treating  pain  in
addition  to  the  inflammatory  process  in CRPS.  However,
inflammation  in  CRPS  may  be largely  neurogenic  (initiated
by  inflammatory  mediators  of  the terminals  of  afferent  noci-
ceptors)  and  no  drug has  been  studied  for this type  of
inflammation.22
NSAIDs  represent  first-line  treatment,  especially  in the
early  stages  and  at non-specialized  units,  although  their
efficacy  specifically  for  CRPS  is  unproven,  and  they  are
not  prescribed  in the  treatment  of  neuropathic  pain.  In
initial phases  they  can  be prescribed  for treatment  of
inflammation.23
Oral  corticosteroids  are the only  anti-inflammatory  drugs
for  which there  is  direct  evidence  from  CRPS  clinical  trials
(evidence  level 1).  Most trials  included  acute  cases,  when
inflammation  is  more  common,  and  it  is  unknown  if  corti-
costeroids  offer  a similar  benefit  for chronic  CRPS,  where
levels  of  proinflammatory  cytokines  are  lower,  or  in CRPS
cases  with  only  mild  inflammation.  A short  course  of  steroids
may  be indicated  early  in  CRPS  with  prominent  inflamma-
tion,  but  in  longer  courses  there  are  contraindications  to
chronic  use  of steroids.22
Both minor  (tramadol)  and major (morphine,  oxycodone,
fentanyl,  hydromorphone,  buprenorphine)  opioids  have
their  place  in moderate-severe  pain  that  is  difficult  to  con-
trol,  and  they  have  demonstrated  efficacy  in  neuropathic
pain.4
Antiepileptics  (gabapentin)  and  tricyclic  antidepressants
(amitriptyline)  and  pregabalin  have been  used  as  adjuvants
in  the treatment  of  CRPS.  There  are no  controlled  trials  of
CRPS  type  I  with  these  drugs,  but  their  efficacy  has been
demonstrated  in  the treatment  of  neuropathic  pain.  These
act  by  inhibiting  pain  pathways  and  neuronal  plasticity,  and
are  prescribed  in  acute  phases  with  nerve  injury,  nerve
ectopic  activity  or  chronic  phases.4
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Free  radical  scavengers  have  shown  some  efficacy  in
the  prevention  and  treatment  of  CRPS,  although  in acute
phases  and  with  moderate  involvement.  Vitamin  C  at  doses
of  500  mg/day  and  N-acetyl  cysteine  at  600  mg/day  have
shown  efficacy  in the prevention  of CRPS  in patients  who
have  suffered  wrist  fractures.  Dimethyl  sulfoxide  50%  cream
seems  to reduce  pain  and  inflammation  of the  limb  in the
acute  phase.4
There  is  evidence  that  several  bisphosphonates  have an
acceptable  safety  profile  and  can  significantly  relieve  spon-
taneous  pain  and  improve  the functional  status  of  patients
with  an  early  disease  (duration  of  6 months)  and  with
an  abnormal  uptake  on  the  3-phase  bone  scan.  There  are
indications  that  the doses  necessary  to  achieve  long-term
remission  are  very  high,  i.e.,  neridronate  at  100  mg or
pamidronate  at  90  mg,  each given  via  IV  four  times  over
a  period  of  10  days.  Bisphosphonates  have  analgesic  prop-
erties  that  go beyond  their  effect  on bone  metabolism,
and  preclinical  data  suggest  that  they  have  antinociceptive
effects  in animal models  of  neuropathic  pain.  Therefore,
their  efficacy  cannot  be  limited  to  patients  with  CRPS-
related  bone  pain, but  relevant  clinical  data  are not  yet
available.9
The  recent  use  of  ketamine,  a  potent  agonist  of  N-
methyl-d-aspartate  (NMDA),  in  the management  of  CRPS-I,  is
due  to the  phenomenon  of  central  sensitization.  This  central
sensitization  is  expressed  mainly  in the first  relay  of  nocicep-
tive  information  integration,  where  the  synapses  formed  by
the  central  ends of the A  and  C  fiber  nociceptors  to  noci-
ceptive  neurons  in the  dorsal  horn of  the spinal  cord  are
very  active.  Several  ketamine  dosing  schemes  have been
tested,  from  transcutaneous  application  to  coma  induced  by
ketamine.  Although  lower  doses  seem  to  provide  the best
results,  the lack  of  regulatory  approval  for  this indication
and  various  side  effects  limit  the  use  of  ketamine  in current
practice.8
Topical  anesthetics  such  as  lidocaine  cream  or  transder-
mal  absorption  patches  at 5%,  can  be  suitable  in cases  of
allodynia  and/or  hyperalgesia.22
Interventional  techniques
Sympathetic  nerve  block  is  a treatment  option  for  patients
who  are  refractory  to  pharmacological  treatments,  espe-
cially  when  performed  early  in  the  course  of the disease.24
Nerve  blockage  improves  short-term  pain  and  joint  mobility
and  its effectiveness  is  greater  when  performed  in  the early
stages  of  the  disease,  although  there  are few reliable  studies
and  a  few controlled  studies  that  have  failed  to  demonstrate
long-term  efficacy.  Blockage  provides  a pain-free  period  that
improves  limb  mobility,  allowing  performance  of intensive
physiotherapy,  especially  when  using continuous  techniques,
such  as local  anesthetic  infusion  via  an auxiliary  or  lumbar
epidural  catheter.4
Some  uncontrolled  studies  have  shown  initial  improve-
ment  in pain  after  percutaneous  sympathectomy,  but  there
is  a  high  risk  of  recurrence  between  6 months  and  2 years,
with  neuralgia  and  post-sympathectomy  pain  (up  to  10%.).9
Placement  of  a  cervical  or  lumbar  spinal  epidural  neu-
rostimulator  for posterior  column  spinal cord  stimulation
may  be  an  option  in severe  disabling  pain  in CRPS cases that
have  not  responded  to other  treatments.  A study  of  36  cases
showed  efficacy  in reducing  pain  and improving  quality  of
life  in both  the  short  and long  term.4
A retrospective  study  found  that  intramuscular  injection
of  botulinum  toxin  A  (BTXA)  in  waist  muscles  of  the  upper
limb  was  beneficial  for  short-term  relief  of  pain  caused  by
CRPS.  There  was  a 43%  reduction  in  local  pain  scores  4 weeks
after  intramuscular  injections  of  BTXA.  Studies  that  prove  its
efficacy  and support  its use  in the  long-term  treatment  of
CRPS  are still  lacking.25
Rehabilitation
Early  rehabilitation  is  essential  to  try  to  prevent  muscle
atrophy  and  contractures,  which  in extreme  cases  can  be
irreversible,  although  it requires  the  active  participation  of
the  patient  and this  is  not  always  possible  due  to  severe  pain
and  associated  psychological  disorders.
Physical  therapy  can reduce  pain  and  improve  limb
mobility,  although  the  intensity  of  treatment  varies  depend-
ing on  the severity  of  the syndrome.  Lymphatic  drainage
can  improve  edema.  Transcutaneous  electrical  stimulation
(TENS)  may  improve  pain,  although  its use  is  not  recom-
mended  in  patients  with  severe  allodynia  or  hyperalgesia.
Occupational  therapy  can also  enhance  limb  function  and
coordination.
Some studies  suggest  that  mirror  therapy  may  have  a role
in  the  treatment  of  CRPS.  The  patient  performs  the exercises
in  front  of  a  mirror,  perpendicular  to  the  midline,  which
only  allows  him/her  to observe  the unaffected  limb  during
treatment;  this  creates a  sense  of normality  of  the affected
limb,  probably  due  to  activation  of  the frontal  cortex,  and
pain  relief,  especially  in acute  phases  of the disease.26
Conclusion
Although  the  exact  causes  of  CRPS  have not yet  been  discov-
ered,  the progress  made  in recent  years  in the  understanding
of  the pathophysiological  mechanisms  involved  in the  dis-
ease  allow  us to  foresee  new  treatment  options  targeting  the
etiology.  Understanding  the etiological  factors  will  lead  to  an
early  diagnosis  and  a better  implementation  of  treatment.
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